Neurophysiological and neurological dysfunction is usually experienced for a short period of time in patients with mild traumatic brain injury (mTBI). However, around 15 % of patients exhibit symptoms months after TBI. Phospholipid (PL) changes have been observed in plasma from mTBI patients at chronic stages, suggesting a role in TBI pathology. We examined long-term plasma phospholipid profiles in a mouse model of mTBI to determine their translational value in reproducing PL changes observed in mTBI patients. Plasma samples were collected at an acute timepoint (24 h post-injury) and at several chronic stages (3, 6, 12 and 24 months post-injury) from injured mice and sham controls. Phospholipids were identified and quantified using liquid chromatography/mass spectrometry analysis. In accordance with human data, we observed significantly lower levels of several major PL classes in mTBI mice compared to controls at chronic timepoints. Saturated, monounsaturated and polyunsaturated fatty acids (PUFAs) were differently regulated over time. As PUFA levels were decreased at 3 months, we measured levels of malondialdehyde to assess lipid peroxidation, which we found to be elevated at this timepoint. Ether-containing PE species were elevated at 24 h post-injury and decreased relative to controls at chronic stages. Arachidonic acid and docosahexaenoic acid-containing species were significantly decreased within all PL classes at the chronic stages. Our findings are similar to changes in PL levels observed in human mTBI subjects. Chronic TBI biomarkers have received little attention, even though disabilities at this stage can be of major importance. Our study provides information on biochemical abnormalities that persist long after the initial injury; these abnormalities may provide useful insight into the continuing pathogenesis and serve as diagnostic biomarkers.
Background:The contribution of apolipoprotein E (APOE) E4 to the cerebrovascular dysfunction in Alzheimer's disease (AD) is characterized by the presence of severe cerebral amyloid angiopathy, increased blood-brain-barrier (BBB) breakdown, reduced cerebral vascularization, and basement membrane thinning in E4 carriers compared to non-carriers. It has also been proposed that the diminished capacity of the apoE4 protein to transport essential polyunsaturated fatty acids (PUFAs) that are required for the structural and functional maintenance and vascular integrity of the brain also contribute to AD pathogenesis. However, it remains to be determined if there are changes in the profiles of phospholipids (PL) and in the expression of lipid transporters within the brain vasculature in relation to the E4 allele and AD diagnosis. Methods:We performed liquid chromatography/mass spectrometry based lipidomic analysis of the cerebrovascular and parenchymal fractions from autopsied human brain tissue of pathologically confirmed AD cases and controls stratified by APOE genotype. In order to determine if there were changes in the expression of lipid transporters in relation to the APOE E4 allele, we performed antibody based examination of the major facilitator superfamily domain containing 2A (mfsd2a) protein in the cerebrovasculature from these subjects. Results: Total phosphatidylcholine (PC) was significantly lower in the cerebrovascular fractions of AD patients compared to controls. While docosahexaenoic acid (DHA) containing PL species were lower in heterozygous E4 AD patients compared to E4 controls in both the cerebrovascular and parenchymal fractions, an ether PC species containing arachidonic acid (AA) was elevated within the cerebrovasculature of E4 carriers relative to non-carriers and was highest among E4 AD specimens compared to E4 controls. We also observed an APOE E4 dependent difference in mfsd2a expression. Among AD patients, E4 homozygotes had lower expression of mfsd2a than E4 heterozygotes and non-carriers. Conclusions: These findings demonstrate that deficiencies in DHA within the brains of APOE E4 carriers may, in part, be due to lower expression of mfsd2a. Thus, targeting this transport mechanism may improve the bioavailability of DHA to the brain of APOE E4 individuals providing a novel approach to the treatment of AD.
precise mechanisms are not clear. S100A9 mutations are rarely variants, and it has not been reported in the world. Methods: This study reports a novel S100A9 gene mutation in 5 Malaysian patient with AD. Direct sequencing of the S100A9 gene revealed a novel mis-sense mutation at codon 99 for predicting glucine to lysine substitution (E99K). Results: Additionally, dataset sequence of 60,706 unrelated individuals were screened, which could be used in the various disease-specific and population genetic studies. Conclusions: E99K is a novel S100A9 gene mutation responsible for AD in East Asia as well as in the world.Background: The apolipoprotein (APOE) e4 allele is one of the strongest genetic risk factors for Alzheimer's disease (AD). While the apoE4 protein is well known for its limited capacity to transport lipids, little examination has been performed on blood lipids in the context of the e4 status and their collective contributions to AD. Methods: Lipidomic analyses were performed on serum samples from a longitudinal cohort of cognitively normal subjects, a subset of whom converted to mild cognitive impairment (MCI)/AD within 2 to 3 years. To examine lipids in relation to the APOE genotypes and AD pathology in a mouse model, we performed lipidomic profiling of plasma samples from human APOE targeted replacement mice (APOE-TR) and APOE-TR mice crossed with mice harboring 5 AD mutations (EFAD). To gain a mechanistic understanding of the differences in lipid transport in relation to the e4 allele, we assessed arachidonic acid (AA) and docosahexaenoic acid (DHA) transit in an in vitro blood brain barrier (BBB) model in the presence of different apoE isoforms. Results: Serum from cognitively normal e4 carriers who converted to MCI/ AD had increased AA/DHA ratios in major phospholipid (PL) classes compared to non-carriers and cognitively normal e4 carriers. Combining these PL species, e4 status, and the Abeta42/40 ratio gave 91% accuracy for detecting preclinical MCI/AD. Both e4 carriers and non-carriers who consumed fish oil/omega-3 had lower AA/DHA ratios within several PL classes compared to non-users. The AA/DHA ratio within PL was increased in plasma from mice expressing human APOE4 relative to E2 or E3 isoforms and in E4FAD mice compared to EFAD animals with other APOE isoforms. In vitro BBB studies showed the apical-to-basolateral transit of both AA and DHA was diminished using human serum from e4/e4 compared to e3/e3 individuals. Conclusions: The elevated AA/DHA ratios within PL observed in serum of e4 carriers with preclinical MCI/AD could be due to impaired lipid transport into the brain. Finally, these studies indicate that determination of AA and DHA containing PL together with APOE genotype could assist in the detection of preclinical MCI/AD. Background:Vascular risk factors (i.e., hypertension, type 2 diabetes, smoking history) cause injuries in regions of the brain that are essential for healthy motor and cognitive function. Motor dysfunction (i.e., gait dysfunction) occurs in older adults with mild co...
The original version of this article unfortunately contained a mistake. Gary S. Laco should not be listed as an author in the author group. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.